• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项使用美国食品药品监督管理局不良事件报告系统(FAERS)数据库,对2013年第四季度至2024年第一季度醋酸艾司利卡西平进行的真实世界药物警戒分析。

A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).

作者信息

Tang Huafei, Xu Jing, Zhang Xian, Chen Chunliang, Song Ge, Ma Rui, Zhao Jinjing, Zhao Qiang

机构信息

Department of Pharmacy, The 305 Hospital of PLA, Beijing, China.

Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.

出版信息

Front Pharmacol. 2024 Sep 20;15:1463560. doi: 10.3389/fphar.2024.1463560. eCollection 2024.

DOI:10.3389/fphar.2024.1463560
PMID:39372199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11449726/
Abstract

BACKGROUND

The approval of eslicarbazepine acetate (ESL) by the Food and Drug Administration (FDA) in 2013 marked an advancement in the treatment of adult patients with partial-onset seizures. However, there still remains a paucity of real-world studies regarding the adverse events (AEs) associated with this compound. The principal aim of the present study was to scrutinize ESL-related AEs by leveraging data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

METHODS

By extracting all available data since the FDA approval of ESL (2013Q4-2024Q1), disproportionality analysis was performed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi-item gamma Poisson shrinker (MGPS) algorithms. AE signals that simultaneously met the requirements of all four algorithms were identified as significant positive signals. Demographic information, time of onset and gender-specific signal detection were also examined. In addition, a special screening process for designated medical events (DME) was implemented to focus on the evaluation and comparison of safety signals within DME and System Organ Classification (SOC) level, as well as SMQ (Standardised MedDRA Queries) level. Stratified analysis by logistic regression is employed to examine the variations across different gender (male and female) and age groups (<18 years old, 18-64 years old, >65 years old).

RESULTS

A total of 5,719 AE reports and 1,907 reported cases were obtained. ESL related AEs were identified in relation to 27 SOCs, among which the significant positive SOCs were nervous system disorders, injury poisoning and procedural complications, etc. There were 86 severely disproportional preferred terms that complied with the four algorithms. Most AEs occurred within the first month after treatment. According to the 86 valuable positive signals with DME screening results, 3 signals of dermatitis exfoliative, stevens-johnson syndrome, drug reaction with eosinophilia and systemic symptoms were consistent with PT signals on the DME-list, with the 3 PTs focusing on skin and subcutaneous tissue disorders and hypersensitivity. Males are more commonly affected by seizures than females. Seizures, hyponatremia, and confusional states were more frequently observed in the elderly population, while aggression, irritability, DRESS (drug reaction with eosinophilia and systemic symptoms), and abnormal behavior were found to be more common in the pediatric population. Both the children and elderly groups exhibited a higher proportion of agitation than the adult group.

CONCLUSION

Our research enhances the safety and tolerability profile of ESL, but the clinical use of ESL should be noticed and avoided in relation to AEs since it raises the risk of dermatitis exfoliative, stevens-johnson syndrome. Particular attention should be paid to DRESS in children and hyponatremia in the elderly.

摘要

背景

2013年美国食品药品监督管理局(FDA)批准醋酸艾司利卡西平(ESL)标志着成人部分性发作患者治疗方面的一项进展。然而,关于该化合物相关不良事件(AE)的真实世界研究仍然匮乏。本研究的主要目的是利用美国食品药品监督管理局不良事件报告系统(FAERS)数据库中的数据,仔细审查与ESL相关的AE。

方法

通过提取自FDA批准ESL以来(2013年第四季度至2024年第一季度)的所有可用数据,使用报告比值比(ROR)、比例报告比值(PRR)、贝叶斯置信传播神经网络(BCPNN)和多项目伽马泊松收缩器(MGPS)算法进行不成比例分析。同时满足所有四种算法要求的AE信号被识别为显著阳性信号。还检查了人口统计学信息、发病时间和性别特异性信号检测。此外,实施了针对指定医疗事件(DME)的特殊筛选过程,以专注于DME和系统器官分类(SOC)级别以及标准化医学术语集(SMQ)级别内安全信号的评估和比较。采用逻辑回归进行分层分析,以检查不同性别(男性和女性)和年龄组(<18岁、18 - 64岁、>65岁)之间的差异。

结果

共获得5719份AE报告和1907例报告病例。确定了与ESL相关的AE涉及27个SOC,其中显著阳性的SOC为神经系统疾病、损伤中毒和手术并发症等。有86个严重不成比例的首选术语符合这四种算法。大多数AE发生在治疗后的第一个月内。根据86个具有DME筛选结果的有价值的阳性信号,剥脱性皮炎、史蒂文斯 - 约翰逊综合征、药物反应伴嗜酸性粒细胞增多和全身症状这3个信号与DME列表上的PT信号一致,这3个PT集中在皮肤和皮下组织疾病及超敏反应方面。男性比女性更容易受到癫痫发作的影响。癫痫发作、低钠血症和意识模糊状态在老年人群中更常见,而攻击行为、易怒、药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)以及异常行为在儿科人群中更常见。儿童和老年组的激越比例均高于成人组。

结论

我们的研究提高了ESL的安全性和耐受性,但由于ESL会增加剥脱性皮炎、史蒂文斯 - 约翰逊综合征的风险,在临床使用ESL时应注意并避免相关AE。应特别关注儿童中的DRESS和老年人中的低钠血症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/add113803c93/fphar-15-1463560-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/d090eefe9a8d/fphar-15-1463560-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/5a46e05ab655/fphar-15-1463560-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/d6efaa9334b9/fphar-15-1463560-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/12717bbeda80/fphar-15-1463560-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/857ba74c7b72/fphar-15-1463560-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/6a2e9183ab51/fphar-15-1463560-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/ffe1e819959b/fphar-15-1463560-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/add113803c93/fphar-15-1463560-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/d090eefe9a8d/fphar-15-1463560-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/5a46e05ab655/fphar-15-1463560-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/d6efaa9334b9/fphar-15-1463560-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/12717bbeda80/fphar-15-1463560-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/857ba74c7b72/fphar-15-1463560-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/6a2e9183ab51/fphar-15-1463560-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/ffe1e819959b/fphar-15-1463560-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b93/11449726/add113803c93/fphar-15-1463560-g008.jpg

相似文献

1
A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).一项使用美国食品药品监督管理局不良事件报告系统(FAERS)数据库,对2013年第四季度至2024年第一季度醋酸艾司利卡西平进行的真实世界药物警戒分析。
Front Pharmacol. 2024 Sep 20;15:1463560. doi: 10.3389/fphar.2024.1463560. eCollection 2024.
2
Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system.拉考沙胺的真实世界安全性:基于 FDA 不良事件报告系统自发报告的药物警戒研究。
Seizure. 2023 Aug;110:203-211. doi: 10.1016/j.seizure.2023.07.003. Epub 2023 Jul 5.
3
Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.恩福妥滨上市后药物安全性监测:基于真实世界数据库的观察性药物警戒研究。
Front Immunol. 2024 Aug 20;15:1397692. doi: 10.3389/fimmu.2024.1397692. eCollection 2024.
4
Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.在美国食品药品监督管理局不良事件报告系统数据库中报告的利伐沙班疑似药物不良反应:一项药物警戒研究。
Front Pharmacol. 2024 Sep 6;15:1399172. doi: 10.3389/fphar.2024.1399172. eCollection 2024.
5
Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.阿布昔替尼的上市后安全性问题:对美国食品药品监督管理局不良事件报告系统的真实世界药物警戒分析
Expert Opin Drug Saf. 2025 May;24(5):599-606. doi: 10.1080/14740338.2024.2356020. Epub 2024 May 17.
6
Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.戈沙妥珠单抗的上市后安全性监测:一项利用FAERS数据库的观察性药物警戒研究。
Front Pharmacol. 2023 Nov 10;14:1283247. doi: 10.3389/fphar.2023.1283247. eCollection 2023.
7
Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.基于FAERS数据库的鲁马哌酮不良事件信号挖掘及严重不良事件影响因素分析
Front Pharmacol. 2024 Sep 23;15:1472648. doi: 10.3389/fphar.2024.1472648. eCollection 2024.
8
Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.加硫酶的真实世界药物警戒分析:一项基于美国食品药品监督管理局不良事件报告系统(FAERS)数据库的研究
Front Pharmacol. 2024 Aug 5;15:1420126. doi: 10.3389/fphar.2024.1420126. eCollection 2024.
9
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.他法米替尼的安全性评估:FDA 不良事件报告系统(FAERS)事件的真实世界药物警戒研究。
BMC Pharmacol Toxicol. 2024 Sep 27;25(1):71. doi: 10.1186/s40360-024-00790-2.
10
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).一项基于美国食品药品监督管理局不良事件报告系统(FAERS)的泊洛妥珠单抗维布妥昔单抗真实世界药物警戒研究。
Front Pharmacol. 2024 Jun 25;15:1405023. doi: 10.3389/fphar.2024.1405023. eCollection 2024.

本文引用的文献

1
Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.辅助性依佐加巴林酯治疗成年亚洲局灶性癫痫发作患者的长期疗效:III 期试验的事后分析。
Clin Transl Sci. 2024 May;17(5):e13802. doi: 10.1111/cts.13802.
2
Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球、区域和国家神经障碍疾病负担,1990-2021 年:2021 年全球疾病负担研究的系统分析。
Lancet Neurol. 2024 Apr;23(4):344-381. doi: 10.1016/S1474-4422(24)00038-3. Epub 2024 Mar 14.
3
Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: A safety perspective.
英国和爱尔兰共和国使用醋酸艾司利卡西平13年的经验:安全性视角
Epileptic Disord. 2023 Dec;25(6):803-814. doi: 10.1002/epd2.20146. Epub 2023 Aug 26.
4
Adult epilepsy.成人癫痫。
Lancet. 2023 Jul 29;402(10399):412-424. doi: 10.1016/S0140-6736(23)01048-6. Epub 2023 Jul 14.
5
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.用于局灶性癫痫的艾司利卡西平醋酸盐的三项 III 期临床试验中的精神不良事件。
Epilepsia Open. 2022 Dec;7(4):616-632. doi: 10.1002/epi4.12635. Epub 2022 Aug 30.
6
The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects.艾司利卡西平醋酸盐在韩国人群和白种人群中的药代动力学、安全性和耐受性特征具有可比性。
Clin Transl Sci. 2022 Sep;15(9):2116-2126. doi: 10.1111/cts.13344. Epub 2022 Jun 21.
7
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.抗癫痫药物单药治疗癫痫:一项个体参与者数据的网络荟萃分析。
Cochrane Database Syst Rev. 2022 Apr 1;4(4):CD011412. doi: 10.1002/14651858.CD011412.pub4.
8
ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics.ABCB1 C3435T、G2677T/A 和 C1236T 变异对依佐加滨药代动力学没有影响。
Biomed Pharmacother. 2021 Oct;142:112083. doi: 10.1016/j.biopha.2021.112083. Epub 2021 Aug 24.
9
The History of Epilepsy: From Ancient Mystery to Modern Misconception.癫痫的历史:从古代谜团到现代误解
Cureus. 2021 Mar 17;13(3):e13953. doi: 10.7759/cureus.13953.
10
The tolerability and safety profile of eslicarbazepine acetate in neurological disorders.醋酸艾司利卡西平在神经系统疾病中的耐受性和安全性概况。
J Neurol Sci. 2020 Jun 15;413:116772. doi: 10.1016/j.jns.2020.116772. Epub 2020 Mar 11.